Small cap, well covered — what the screen found 2026-11-11
Manufacturing dominates this result, accounting for 26 of the 40 companies that passed the screen on November 10, 2026.
Key figures
Data as of Nov 11, 2026- VNRX (VolitionRx Limited) market cap
- $5.67M
- APRE (Aprea Therapeutics, Inc. Common stock) market cap
- $6.33M
- ACH (Accendra Health, Inc.) market cap
- $11.08M
- AEON (AEON Biopharma, Inc.) market cap
- $12.98M
- SEAT (Vivid Seats Inc. Class A Common Stock) market cap
- $16.76M
- ABOS (Acumen Pharmaceuticals, Inc. Common Stock) market cap
- $16.95M
Manufacturing dominates this result, accounting for 26 of the 40 companies¹˒² that passed the screen on November 10, 2026.
The list identifies smaller names that maintain analyst coverage—a crude proxy for the level of scrutiny applied to their financials. Examples include VolitionRx Limited (VNRX) with a $5.67M market cap³ and Aprea Therapeutics (APRE) at $6.33M⁴. Other manufacturing names include AEON Biopharma (AEON) at $12.98M⁵ and Acumen Pharmaceuticals (ABOS) at $16.95M. Non-manufacturing names also appeared, such as Accendra Health (ACH) in Wholesale Trade with a $11.08M market cap⁶ and Vivid Seats (SEAT) in Services at $16.76M⁷.
Passing this test does not establish that a company is worth owning, nor does it predict future performance. It simply confirms that these 40 names—selected from a pool of 3,478 companies with available data⁸—met specific thresholds on a single date. This is a filter, not a verdict.